Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Pasi A. Janne, Mengzhao Wang, D. Ross Camidge, Paul Mitchell, Jian Fang, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Viola Weijia Zhu, Michael Millward, Yun Fan, Wen-Tsung Huang, Ying Cheng, Liyan Jiang, Daniel Brungs, Li Zheng, James Chih-Hsin Yang

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

6 Citations (Web of Science)
Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume40
Issue number16
Publication statusPublished - 1 Jun 2022
EventAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 3 Jun 20227 Jun 2022

Cite this